Firstly no one is pumping nothing because the company is an 8 million dollar EV with 10 million in cash which there is nothing to pump because it’s already severely undervalued and nothing has been priced in for a drug that works beyond initial modelling and out paced all initial results.
Secondly of course for a stroke there is a limited time window and hence why all hospitals, ambulances and doctors all around the world will have this on hand hence the multi billion dollar market they dominate
Thirdly from his recent interview 4 days ago the CEO clearly stated that the Walter reed will still be completed on time and that on completion a partnership of non dilutive funding is in consideration with the US Army which are the ones that are driving the traumatic brain injury
https://youtu.be/uOFBHxMGtQc?si=mgTUYASMAUWZHOSm
Fourthly if you believe that a company with a drug exceeding all parameters and companies with less superior drugs trading at 70 million dollar market caps with less cash is a 8 million dollar EV you better keep bashing the keyboard that I’m pumping a company not pricing in anything. It’s a 100 million dollar market cap with the results it’s on and with a multi billion dollar run way as each phase study comes into play. The previous all time high before any of these results where know will be taken out. The same road of growth as MSB which you are invested in which was worth 4 billion dollars on a phase 3 potential 2 years ago. Doesn’t go from 8 million dollar EV to a 2-3 billion dollar valuation in a day
- Forums
- ASX - By Stock
- Ann: Quarterly Activities Report and Appendix 4C
NYR
nyrada inc.
Add to My Watchlist
10.6%
!
26.0¢

Firstly no one is pumping nothing because the company is an 8...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
26.0¢ |
Change
0.025(10.6%) |
Mkt cap ! $54.83M |
Open | High | Low | Value | Volume |
23.5¢ | 26.5¢ | 23.5¢ | $352.7K | 1.440M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3600 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 4499 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3600 | 0.240 |
5 | 169261 | 0.235 |
5 | 94773 | 0.220 |
2 | 120005 | 0.215 |
7 | 419378 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 4499 | 1 |
0.265 | 154139 | 2 |
0.270 | 40000 | 1 |
0.275 | 405 | 1 |
0.280 | 117907 | 3 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online